Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Archives of Internal Medicine

• Publication date

  2002-07-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHINTE.162.14.1568PMID 12123399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetic dyslipidemia.

  2002cited by this paper
• Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

  2001cited by this paper
• Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.

  2000cited by this paper
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

  2000cited by this paper
• Mechanism of action of niacin on lipoprotein metabolism

  2000cited by this paper
• Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.

  2000cited by this paper
• Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

  1999cited by this paper
• Insulin resistance and lipid metabolism.

  1999cited by this paper
• Primary prevention of coronary heart disease: integrating risk assessment with intervention.

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• Management of Dyslipidemia in Adults With Diabetes

  1998cited by this paper
• Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.

  1998cited by this paper
• Diabetic dyslipidemia.

  1998cited by this paper
• A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.

  1998cited by this paper
• Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.

  1998influential reference
• Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• The University of Texas Southwestern Medical Center

  1997cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.

  1994cited by this paper
• Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study

  1992cited by this paper
• Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.

  1990influential reference
• Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus.

  1987cited by this paper
• Nicotinic acid-induced fulminant hepatic failure.

  1987cited by this paper
• Diabetes and atherosclerosis: an epidemiologic view.

  1987cited by this paper
• Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.

  1985cited by this paper
• Clofibrate and niacin in coronary heart disease.

  1975cited by this paper

• Mechanisms, precision therapies, and technological frontiers in coronary atherosclerosis: a comprehensive review.

  2026cites this paper
• GLYCAEMIC CONTROL PROFILE IN DIABETIC PATIENTS: A SUB-ANALYSIS OF THE PHOENIX LIFESTYLE PROJECT

  2026cites this paper
• Oral Niacin and Topical Nitroglycerin to Prevent Nicotine-Related Complications Following Facelift Surgery

  2025cites this paper
• NAD in pathological cardiac remodeling: Metabolic regulation and beyond.

  2024cites this paper
• The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Severe hypertriglyceridemia: Existing and emerging therapies.

  2023cites this paper
• Gender-specific effects of oxidative balance score on the prevalence of diabetes in the US population from NHANES

  2023cites this paper
• Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial

  2022cites this paper
• Lipoprotein (a) and diabetes mellitus.

  2022cites this paper
• Assessment of dietary intake by self-report in adult patients with type 1 diabetes treated with a personal insulin pump

  2022cites this paper
• Relationship between Habitual Intake of Vitamins and New-Onset Prediabetes/Diabetes after Acute Pancreatitis

  2022cites this paper
• Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5

  2022cites this paper
• Nicotinic acid, its mechanism of action and pharmacological effects

  2021cites this paper
• A Comparative Study on Efficacyof Lutein and Atorvastatin on Lipid Profile & Lipoprotein(a) in Hypercholesterolemic Male Wistar Rats

  2021cites this paper
• Regulation of NAD+ metabolism in aging and disease.

  2021cites this paper
• Recommandations récentes dans les dyslipidémies du diabétique : commentaire à partir de trois cas cliniques

  2021cites this paper
• Updated management of dyslipidaemia in diabetes: A new step towards more stringent targets

  2021cites this paper
• Niacin supplementation impairs exercise performance.

  2021cites this paper
• Effects of Hydroalcoholic Extracts of Cloves (Syzygium aromaticum) on the Serum Biomarkers, Antioxidant Status, and Histopathological Changes of Kidneys in Diabetic Rats

  2021cites this paper
• Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction

  2021cites this paper
• Atherosclerosis

  2020cites this paper
• Short-term effects induced by nicotinamide in ovariectomized females.

  2020cites this paper
• Effectiveness of niacin supplementation for patients with type 2 diabetes

  2020cites this paper
• Vitamin Toxicities and Therapeutic Monitoring

  2020cites this paper
• A meta-analysis of randomized controlled trials of virtual reality exposure therapy for post-traumatic stress disorder

  2020cites this paper
• Lipoprotein (a) and diabetes mellitus: causes and consequences.

  2020cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Diabetes Mellitus Types I and II

  2020cites this paper
• Effects of nutritional status on serum fetuin-A level

  2020cites this paper
• Hypertriglyceridemias and Their Treatment

  2019cites this paper
• Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

  2019cites this paper
• Retraction Retracted: A Comprehensive Review on Metabolic Syndrome

  2019cites this paper
• Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.

  2019cites this paper
• Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes

  2019cites this paper
• Monounsaturated Fatty Acids in a High-Fat Diet and Niacin Protect from White Fat Dysfunction in the Metabolic Syndrome.

  2019cites this paper
• A Randomized, Placebo‐Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High‐Density Lipoprotein Cholesterol in Subjects With Dyslipidemia

  2019cites this paper
• Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care

  2018cites this paper
• TEMD DİSLİPİDEMİ TANI ve TEDAVİ KILAVUZU

  2018cites this paper
• Hydroxytyrosol nicotinate, a new multifunctional hypolipidemic and hypoglycemic agent.

  2018cites this paper
• Sobre las asociaciones entre los lípidos séricos y el riesgo cardiovascular

  2018cites this paper
• Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease: summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA)

  2017cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

  2017cites this paper
• Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments

  2017cites this paper
• Interplay between proteins and metabolic syndrome–A review

  2017cites this paper
• Niacin for primary and secondary prevention of cardiovascular events.

  2017cites this paper
• Association of British Clinical Diabetologists-Renal Association ( ABCD-RA ) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and / or Chronic Kidney Disease

  2017cites this paper
• Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes.

  2017cites this paper
• Medication‐induced diabetes mellitus

  2016cites this paper
• Chapter 42 – Hyperglycemia Secondary to Nondiabetic Conditions and Therapies

  2016cites this paper
• Chapter 41 – Lipoprotein Metabolism and the Treatment of Lipid Disorders

  2016cites this paper
• Effect of niacin on triglyceride‐rich lipoprotein apolipoprotein B‐48 kinetics in statin‐treated patients with type 2 diabetes

  2016cites this paper
• Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease

  2016cites this paper
• Effects of Nutrient Supplements and Nutraceuticals on Risk for Cardiovascular Disease

  2016cites this paper
• Optimizing nicotinic acid delivery for durable antilipolysis and improved metabolic control

  2016cites this paper
• Exercise Training eduction in C-Reactive Protein Through ardiac Rehabilitation and Exercise Training

  2016cites this paper
• Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials.

  2016cites this paper
• Niacin: old habits die hard

  2016cites this paper
• Utjecaj antropometrijskih parametara i metaboličkoga sindroma na težinu i prognozu akutnoga infarkta miokarda sa ST-elevacijom

  2015influential citation
• Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials.

  2015cites this paper
• Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus

  2015cites this paper
• Dosing profile profoundly influences nicotinic acid’s ability to improve metabolic control in rats

  2015cites this paper
• Diabetes and Dyslipidemia

  2015cites this paper
• Clinical Study on Apolipoprotein E Distribution, Metabolism and Glycation

  2015cites this paper
• Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.

  2015cites this paper
• Ocular Effects of Niacin: A Review of the Literature

  2015cites this paper
• GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial.

  2015cites this paper
• Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?

  2015cites this paper
• α-Lipoic acid as a triglyceride-lowering nutraceutical.

  2015cites this paper
• Niacin: Risk Benefits and Role in Treating Dyslipidemias

  2015cites this paper
• Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome

  2015cites this paper
• Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.

  2015cites this paper
• Niacin improves adiponectin secretion, glucose tolerance and insulin sensitivity in diet-induced obese rats

  2015influential citation
• Statins and Niacin: The End of Residual Risk Therapy?

  2015cites this paper
• Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

  2015cites this paper
• Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases.

  2014cites this paper
• Lipids and lipid management in diabetes.

  2014cites this paper
• A Comprehensive Review on Metabolic Syndrome

  2014cites this paper
• Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies

  2014cites this paper
• Nowy rok, stare problemy, ale i nowe możliwości

  2014cites this paper
• Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus

  2014cites this paper
• Are add-on agents to statin therapy necessary in hypercholesterolemia?

  2014cites this paper
• Effect of Niacin on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Statin-Treated Patients With Type 2 Diabetes Mellitus

  2014cites this paper
• Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications

  2014cites this paper
• 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients

  2014cites this paper
• Nicotinic Acid Effects on Insulin Sensitivity and Hepatic Lipid Metabolism: An In Vivo to In Vitro Study

  2014cites this paper
• Therapeutic Class Overview Attention Deficit/Hyperactivity Disorder (ADHD) Agents and Stimulants

  2014cites this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cites this paper
• Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

  2014cites this paper
• Origin and therapy for hypertriglyceridaemia in type 2 diabetes.

  2014cites this paper
• Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women

  2014cites this paper
• Confronting the residual cardiovascular risk beyond statins: the role of fibrates, omega-3 fatty acids, or niacin, in diabetic patients.

  2014cites this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cites this paper
• Effect of Nicotinic Acid (Vitamin B3 or Niacin) on the lipid profile of diabetic and non – diabetic rats

  2013cites this paper
• HDL functionality and LDL quality : the influence of obesity, obstructive sleep apnoea and pharmacological intervention

  2013cites this paper
• Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study

  2013cites this paper
• NIACIN AND NIACIN / LAROPIPRANT COMBINATION: OPENING NEW HOPES FOR DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES WITH FEW NOVEL ACTIONS

  2013cites this paper
• Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.

  2013cites this paper
• Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose

  2013cites this paper
• The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).

  2013cites this paper